Abstract: The invention relates to a full length Large T tumor antigen of Merkel Cell Polyomavirus (MCV) as a therapeutic target in Merkel Cell Carcinoma (MCC).

Abstract: The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3 receptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z(n) wherein n is 0 or 1 and when n is 1, Z is an amino-acid residue devoid of sulfhydryl group, or is a polypeptide, Cys is the amino-acid residue for Cysteine, T is a molecule linked by a covalent bound to the S part of Cys, selected in a group comprising: agents for in vivo diagnosis, cytotoxic agents, prodrugs, or enzymes for the conversion of a prodrug to a drug, Y(m) wherein m is 0 or 1 and when m is 1, Y is a linker between T and Cys, said linker being either cleavable or not cleavable for the release of T after the internalization of the hybrid compound into said cells.

Abstract: The invention relates to a microfluidic device comprising at least one micro-channel connected at one end to an enclosed area, characterized in that it also comprises an inlet circuit and an outlet circuit connected to the enclosed area and between which the fluid can be discharged without any contact with the micro-channel, wherein at least one of said inlet and outlet circuits can be controlled in such a way that the pressure at the end of the micro-channel can be modified independently from the pressure at the other end of the micro-channel.

Abstract: The present invention relates to the use of a Shiga toxin B-subunit moiety as carrier for therapeutic agents, for example, anti-cancer agents such as anti-cancer agents that require intracellular uptake to exert their anti-cancer effects. In particular, the present invention provides conjugates comprising a Shiga toxin moiety covalently linked to an anti-cancer agent through a self-immolative spacer, and methods of using such conjugates to increase cellular uptake and/or specificity for cancer cells of the anti-cancer drug. Also provided are methods of treatment involving administration of such conjugates, and pharmaceutical compositions and kits useful for carrying out such methods of treatment.

Abstract: The present invention relates to methods and devices for adhering cells in a specific and predetermined position with an adhesive control of internal cell organization, methods for preparing such devices, methods for studying modifications of cell shape and global internal cell organization such as the distribution of cellular compartments, centrosome centering, spindle orientation, internal compartmentalization and internal transports, methods for screening compounds of interest which enhance or inhibit specific cell functions.

Abstract: The present invention is directed to the use of the expression level of the pro-EPIL gene as a biomarker for the diagnosing of testicular cancer, particularly a testicular germ cell tumor. The invention also relates to an in vitro method for detecting and/or classifying a testicular cancer in a subject comprising a step of determining the expression level of the gene encoding the pro-EPIL peptide in a biological, particularly in combination with the determination of the beta subunit HCG? and the human alpha-fetoprotein AFP. The invention is also directed to a kit or solid support comprising nucleic acids or antibodies capable of determining the presence or the expression level of these three biological markers.

Abstract: Method for producing a comb-shaped copolymer whose skeleton is of an acrylamide, acrylic acid, acryloyl aminoethanol or dimethyl acrylamide type and on which poly(N-alkyl acrylamide) or poly(N,N-5 dialkyl acrylamide lateral segments are grafted, includes (a) producing a telomer poly(N-alkyl acrylamide) or poly(N,N-dialkyl acrylamide) of formula (I) H2N—R1-Z-{CH2—C(R2) [C(?O)N(R3) (R4)]—}n—H (I) 10 by reacting in water a compound of formula (II) CH2?C(R2)—C(?O)—N(R3) (R4) (II) with a chain limiting compound of formula (III) Z-R1—NH2; (b) isolating the telomer of formula (I) obtained at a stage (a); (c) reacting in water the telomer of formula (I) obtained at stage (b) with an acid chloride of formula (IV) CH2?C(R5)—C(?O)—C1 at a molar ratio (IV)/(III) equal to or less than 10 and equal to or greater than 1 so that a macro monomer of formula (V) 20 CH2?C(R5)—C(?O)NH—R1-Z-{CH2—C(R2) [C(?O)N(R3) (R4)]—}n—H (V) is obtained; (d) isolating the macro monomer of formula (V) obtained at stage (c); (e) copolymerizing in

Abstract: The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.

Abstract: The present invention relates to new methods of treatment of cancer, in particular of breast cancer, and methods of screening of compounds useful in the treatment of cancer. The present invention further provides new prognostic and/or diagnostic markers in human cancer.

Abstract: The present invention relates to novel pharmaceutical or cosmetic compositions comprising at least one inhibitor of a sub-unit of AP-1 adaptor complex, of a kinesin interacting with AP-1, in particular Kif13A, or of the interaction between a sub-unit of AP-1 adaptor complex and said kinesin, as well as the use of same to manufacture a drug intended for the treatment of pigmentary disorders and as a depigmentation agent.

Abstract: A method for assessing the proliferative state of cells in a human or non-human biological sample uses Chromatin Assembly Factor-1 (CAF-1) subunits as proliferation markers. The method can be used for breast cancer prognosis or diagnosis, and monitoring tumor response in therapy.

Abstract: The invention pertains to methods for using chimeric polypeptides of the formula: B-X wherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B-X are also included.

Abstract: The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocyte cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocyte cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocyte cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein.

Abstract: The invention relates to methods of modulating an immune response in a mammal by modulating the activity of J?33 T cells or of MR1 polypeptide in vitro, ex vivo or in vivo. The invention also relates to methods of regulating the activity of immune cells, particularly of T lymphocytes and/or B lymphocytes by regulating the activity of MR1 in vitro, ex vivo or in vivo. The invention further comprises methods of screening active compounds using MR1 or fragments thereof, or nucleic acid encoding the same, or recombinant host cells expressing said polypeptide. The invention also deals with a pharmaceutical composition comprising J?33 T cells, MR1 polypeptide or a compound that modulates the activity of J?33 TCR T cells or of MR1 polypeptide and a pharmaceutically acceptable vehicle or carrier. The invention further deals with methods of diagnosis for intestinal diseases related to a defect of the activity of said J?33 T cells or MR1 polypeptide.

Abstract: The instant application provides a pharmaceutical composition comprising an antibody, directed against Tn antigen which comprises CDRs derived from 83D4 monoclonal antibody or an immunoconjugate of said antibody, said pharmaceutical composition being intended for the treatment of cancer.

Abstract: The invention relates to a method for assessing the proliferative state of cells in a human or non human biological sample, comprising using Chromatin Assembly Factor-1 (CAF-1 in short) subunits as proliferation markers. Application for cancer prognosis or diagnosis and monitoring tumor response in therapy.

Abstract: The present invention relates to a composition comprising a) a B subunit of Shiga toxin or a functional equivalent thereof which is able to bind the Gb3 receptor, complexed with an antigen and b) at least one ligand of CDI capable of stimulating NK T cells; and to a pharmaceutical composition and a medicament comprising said composition.

Abstract: The present invention concerns methods and compositions for treating bladder carcinoma by p38 inhibitors.

Abstract: The invention relates to compositions and methods for interfering with the DNA repair of double strand breaks (DSBs). The invention discloses novel double-stranded nucleic acid molecules. that act as baits and hijack the holocomplex of enzymes responsible of DNA DSB sensing, signaling and/or repair pathways, in particular the non homologous end joining (NHEJ) pathway of DSB repair. The invention discloses the use of these molecules as adjuvant compositions to be used in association with a DNA breaking treatment, particularly radiotherapy or chemotherapy, in combination with a pharmaceutically acceptable carrier, in an efficient amount to be introduced in the tumor cell nuclei in order to neutralize transiently their DNA repair capacity and trigger their death.

Abstract: A method for the in vitro diagnosis of colorectal cancer by determining the presence of the I-Plastin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.